UBS analyst Marc Goodman reiterated a Buy rating and boosted his price target on Allergen (NYSE: AGN) to $366.00 (from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Canaccord Genuity Raises Price Target on Allergan (AGN) Following Announced Generics Sale July 28, 2015 9:13 AM Leerink Partners Raised Price Target on Allergan (AGN) to $388 Following TEVA Announcement July 28, 2015 8:19 AM Teva Pharma (TEVA) to Acquire Allergan Genetics (AGN) in $40.5B Cash and Stock DealJuly 27, 2015 6:03 AM Teva to Acquire Allergan Generics for $40.5 Billion Creating a Transformative Generics and Specialty Company Well Positioned to Win in Global HealthcareJuly 27, 2015 4:30 AM